{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:13:13Z","timestamp":1792181593570,"version":"4.4.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:p>Mucormycosis is a rare but life-threatening fungal infection caused by Mucorales, with high morbidity and mortality rates, especially among immunocompromised individuals. We report six cases of rare manifestations of cutaneous mucormycosis. To describe rare manifestations of cutaneous mucormycosis, highlighting the importance of prompt recognition and treatment to improve patient outcomes. Retrospective review of medical records from 2021 to 2023. This case series presents six patients with rare manifestations of cutaneous mucormycosis. The patients\u2019 ages ranged from 25 to 60 years, with an equal male-to-female ratio. Comorbidities included diabetes, HIV\/AIDS, chronic kidney disease, connective tissue disorder, leukemia, and systemic lupus erythematosus (SLE). All six patients (100%) presented with cutaneous mucormycosis, with varying clinical manifestations, including necrotizing fasciitis of the scalp (16.7%), cutaneous lesions of the buttock (16.7%), fungal keratitis and endophthalmitis with periorbital cutaneous lesions (16.7%), mucormycotic abdominal wall lesions (16.7%), mucormycotic osteomyelitis of the mandible with overlying skin blackening (16.7%), and cerebral vasculitis with scalp skin lesions (16.7%). The most common clinical features are fever (83.3%), pain (66.7%), and swelling (50%). Laboratory findings include elevated WBC count (83.3%), positive fungal culture (100%), and histopathology (83.3%). Treatment consisted of surgical debridement (83.3%), antifungal therapy with amphotericin B (100%), and supportive care. Outcomes were favorable, with one patient achieving complete recovery (16.7%), four showing improvement (66.7%), and one experiencing disease stabilization (16.7%). Notably, no mortality was reported. Cutaneous mucormycosis can manifest in diverse ways. Early recognition and treatment are crucial to prevent morbidity and mortality associated with this rare and devastating fungal infection.<\/jats:p>","DOI":"10.4103\/jfmpc.jfmpc_1603_24","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T10:01:43Z","timestamp":1751277703000},"page":"2561-2564","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Cutaneous mucormycosis: Unveiling rare manifestations"],"prefix":"10.4103","volume":"14","author":[{"given":"Jyoti","family":"Jindal","sequence":"first","affiliation":[{"name":"Department of Medicine, Dayanand Medical College and Hospital, Ludhiana, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dayanand Medical College and Hospital, Ludhiana, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"issue":"Suppl 1","key":"R1-20250707","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/cid\/cir866","article-title":"Epidemiology and clinical manifestations of mucormycosis","volume":"54","author":"Petrikkos","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"R2-20250707","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/cir880","article-title":"A global analysis of mucormycosis in France: The RetroZygo study (2005-2007)","volume":"54","author":"Lanternier","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R3-20250707","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/jof6040265","article-title":"Epidemiology and diagnosis of mucormycosis: An update","volume":"6","author":"Skiada","year":"2020","journal-title":"J Fungi (Basel)"},{"issue":"Suppl 3","key":"R4-20250707","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/myc.12243","article-title":"Mucormycosis in India: Unique features","volume":"57","author":"Chakrabarti","year":"2014","journal-title":"Mycoses"},{"issue":"Suppl 1","key":"R5-20250707","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1470-9465.2004.00843.x","article-title":"Mucormycosis and entomophthoramycosis: A review of the clinical manifestations, diagnosis and treatment","volume":"10","author":"Prabhu","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"R6-20250707","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/myc.12428","article-title":"Delaying diagnostic procedure significantly increases mortality in patients with invasive mucormycosis","volume":"58","author":"Jeong","year":"2015","journal-title":"Mycoses"},{"key":"R7-20250707","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1086\/599105","article-title":"Recent advances in the management of mucormycosis: From bench to bedside","volume":"48","author":"Spellberg","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R8-20250707","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1590\/abd1806-4841.20176614","article-title":"Cutaneous mucormycosis","volume":"92","author":"Castrej\u00f3n-P\u00e9rez","year":"2017","journal-title":"An Bras Dermatol"},{"issue":"Suppl 2","key":"R9-20250707","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/jac\/dkac352","article-title":"Liposomal amphotericin B\u2014the present","volume":"77","author":"Maertens","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R10-20250707","doi-asserted-by":"crossref","first-page":"101332","DOI":"10.1016\/j.mycmed.2022.101332","article-title":"Combination therapy in Mucormycosis: Current evidence from the world literature, a mini review","volume":"33","author":"Meena","year":"2023","journal-title":"J Mycol Med"},{"issue":"Suppl 3","key":"R11-20250707","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 3","key":"R13-20250707","first-page":"47","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: Diseases caused by black fungi","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R14-20250707","doi-asserted-by":"crossref","first-page":"100607","DOI":"10.1016\/j.mmcr.2023.100607","article-title":"Cutaneous mucormycosis in the immunocompromised host: An important cause of persistent post traumatic skin lesions","volume":"42","author":"Beliavsky","year":"2023","journal-title":"Med Mycol Case Rep"},{"key":"R15-20250707","doi-asserted-by":"crossref","first-page":"1254919","DOI":"10.3389\/fcimb.2023.1254919","article-title":"Mucormycosis in, 2023: An update on pathogenesis and management","volume":"13","author":"Alqarihi","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"Suppl 3","key":"R16-20250707","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/1469-0691.12515","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: Diseases caused by black fungi","volume":"20","author":"Chowdhary","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R17-20250707","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/encyclopedia2010016","article-title":"Mucormycosis\u2014emerging fungal threats","volume":"2","author":"Troiano","year":"2022","journal-title":"Encyclopedia"},{"key":"R18-20250707","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/QCO.0000000000000976","article-title":"Mucormycosis: Update on clinical presentation, diagnosis, and treatment","volume":"36","author":"Dailey","year":"2023","journal-title":"Curr Opin Infect Dis"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1603_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:35:20Z","timestamp":1787067320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1603_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1603_24","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2024-09-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}